Copyright Reports & Markets. All rights reserved.

Dynamics in Post-pandemic Global Cancer Tubulin Inhibitors Industry: Supply and Demand, Markets and Prices 2021-2027

Buy now

Table of Contents

    1 Product Introduction and Overview

    • 1.1 Product Definition
    • 1.2 Product Specification
    • 1.3 Global Market Overview
      • 1.3.1 Global Cancer Tubulin Inhibitors Market Status and Forecast (2016-2027)
      • 1.3.2 Global Cancer Tubulin Inhibitors Sales Value CAGR by Region
    • 1.4 Market Drivers, Inhibitors
      • 1.4.1 Market Drivers
      • 1.4.2 Market Inhibitors
      • 1.4.3 COVID-19 Impact Analysis

    2 Global Cancer Tubulin Inhibitors Supply by Company

    • 2.1 Global Cancer Tubulin Inhibitors Sales Volume by Company
    • 2.2 Global Cancer Tubulin Inhibitors Sales Value by Company
    • 2.3 Global Cancer Tubulin Inhibitors Price by Company
    • 2.4 Cancer Tubulin Inhibitors Production Location and Sales Area of Main Manufacturers
    • 2.5 Trend of Concentration Rate

    3 Global and Regional Cancer Tubulin Inhibitors Market Status by Category

    • 3.1 Cancer Tubulin Inhibitors Category Introduction
      • 3.1.1 Docetaxel
      • 3.1.2 Trastuzumab Emtansine
      • 3.1.3 Abraxane
      • 3.1.4 Brentuximab Vedotin
      • 3.1.5 Cabazitaxel
    • 3.2 Global Cancer Tubulin Inhibitors Market by Category
      • 3.2.1 Global Cancer Tubulin Inhibitors Sales Volume by Category (2016-2021)
      • 3.2.2 Global Cancer Tubulin Inhibitors Sales Value by Category (2016-2021)
      • 3.2.3 Global Cancer Tubulin Inhibitors Price by Category (2016-2021)
    • 3.3 North America: by Category
    • 3.4 Europe: by Category
    • 3.5 Asia Pacific: by Category
    • 3.6 Central & South America: by Category
    • 3.7 Middle East & Africa: by Category

    4 Global and Regional Cancer Tubulin Inhibitors Market Status by End User/Segment

    • 4.1 Cancer Tubulin Inhibitors Segment by End User/Segment
      • 4.1.1 Non Small Cell Lung Cancer
      • 4.1.2 Prostate Cancer
      • 4.1.3 Breast Cancer
      • 4.1.4 Colorectal Cancer
      • 4.1.5 Ovarian Cancer
    • 4.2 Global Cancer Tubulin Inhibitors Market by End User/Segment
      • 4.2.1 Global Cancer Tubulin Inhibitors Sales Volume by End User/Segment (2016-2021)
      • 4.2.2 Global Cancer Tubulin Inhibitors Sales Value by End User/Segment (2016-2021)
      • 4.2.3 Global Cancer Tubulin Inhibitors Price by End User/Segment (2016-2021)
    • 4.3 North America: by End User/Segment
    • 4.4 Europe: by End User/Segment
    • 4.5 Asia Pacific: by End User/Segment
    • 4.6 Central & South America: by End User/Segment
    • 4.7 Middle East & Africa: by End User/Segment

    5 Global Cancer Tubulin Inhibitors Market Status by Region

    • 5.1 Global Cancer Tubulin Inhibitors Market by Region
      • 5.1.1 Global Cancer Tubulin Inhibitors Sales Volume by Region
      • 5.1.2 Global Cancer Tubulin Inhibitors Sales Value by Region
    • 5.2 North America Cancer Tubulin Inhibitors Market Status
    • 5.3 Europe Cancer Tubulin Inhibitors Market Status
    • 5.4 Asia Pacific Cancer Tubulin Inhibitors Market Status
    • 5.5 Central & South America Cancer Tubulin Inhibitors Market Status
    • 5.6 Middle East & Africa Cancer Tubulin Inhibitors Market Status

    6 North America Cancer Tubulin Inhibitors Market Status

    • 6.1 North America Cancer Tubulin Inhibitors Market by Country
      • 6.1.1 North America Cancer Tubulin Inhibitors Sales Volume by Country (2016-2021)
      • 6.1.2 North America Cancer Tubulin Inhibitors Sales Value by Country (2016-2021)
    • 6.2 United States
    • 6.3 Canada
    • 6.4 Mexico

    7 Europe Cancer Tubulin Inhibitors Market Status

    • 7.1 Europe Cancer Tubulin Inhibitors Market by Country
      • 7.1.1 Europe Cancer Tubulin Inhibitors Sales Volume by Country (2016-2021)
      • 7.1.2 Europe Cancer Tubulin Inhibitors Sales Value by Country (2016-2021)
    • 7.2 Germany
    • 7.3 France
    • 7.4 UK
    • 7.5 Italy
    • 7.6 Russia
    • 7.7 Spain

    8 Asia Pacific Cancer Tubulin Inhibitors Market Status

    • 8.1 Asia Pacific Cancer Tubulin Inhibitors Market by Country
      • 8.1.1 Asia Pacific Cancer Tubulin Inhibitors Sales Volume by Country (2016-2021)
      • 8.1.2 Asia Pacific Cancer Tubulin Inhibitors Sales Value by Country (2016-2021)
    • 8.2 China
    • 8.3 Japan
    • 8.4 Korea
    • 8.5 Southeast Asia
    • 8.6 India
    • 8.7 Australasia

    9 Central & South America Cancer Tubulin Inhibitors Market Status

    • 9.1 Central & South America Cancer Tubulin Inhibitors Market by Country
      • 9.1.1 Central & South America Cancer Tubulin Inhibitors Sales Volume by Country (2016-2021)
      • 9.1.2 Central & South America Cancer Tubulin Inhibitors Sales Value by Country (2016-2021)
    • 9.2 Brazil
    • 9.3 Argentina
    • 9.4 Colombia

    10 Middle East & Africa Cancer Tubulin Inhibitors Market Status

    • 10.1 Middle East & Africa Cancer Tubulin Inhibitors Market by Country
      • 10.1.1 Middle East & Africa Cancer Tubulin Inhibitors Sales Volume by Country (2016-2021)
      • 10.1.2 Middle East & Africa Cancer Tubulin Inhibitors Sales Value by Country (2016-2021)
    • 10.2 Iran
    • 10.3 Israel
    • 10.4 Turkey
    • 10.5 South Africa
    • 10.8 Saudi Arabia

    11 Supply Chain and Manufacturing Cost Analysis

    • 11.1 Supply Chain Analysis
    • 11.2 Production Process Chart Analysis
    • 11.3 Raw Materials and Key Suppliers Analysis
      • 11.3.1 Raw Materials Introduction
      • 11.3.2 Raw Materials Key Suppliers List
    • 11.4 Cancer Tubulin Inhibitors Manufacturing Cost Analysis
    • 11.5 Cancer Tubulin Inhibitors Sales Channel and Distributors Analysis
      • 11.5.1 Cancer Tubulin Inhibitors Sales Channel
      • 11.5.2 Cancer Tubulin Inhibitors Distributors
    • 11.6 Cancer Tubulin Inhibitors Downstream Major Buyers

    12 Global Cancer Tubulin Inhibitors Market Forecast by Category and by End User/Segment

    • 12.1 Global Cancer Tubulin Inhibitors Sales Volume and Sales Value Forecast (2022-2027)
    • 12.2 Global Cancer Tubulin Inhibitors Forecast by Category
      • 12.2.1 Global Cancer Tubulin Inhibitors Sales Volume Forecast by Category
      • 12.2.2 Global Cancer Tubulin Inhibitors Sales Value Forecast by Category
      • 12.2.3 Global Cancer Tubulin Inhibitors Price Forecast by Category
    • 12.3 Global Cancer Tubulin Inhibitors Forecast by End User/Segment
      • 12.3.1 Global Cancer Tubulin Inhibitors Sales Volume Forecast by End User/Segment
      • 12.3.2 Global Cancer Tubulin Inhibitors Sales Value Forecast by End User/Segment
      • 12.3.3 Global Cancer Tubulin Inhibitors Price Forecast by End User/Segment

    13 Global Cancer Tubulin Inhibitors Market Forecast by Region/Country

    • 13.1 Global Cancer Tubulin Inhibitors Market Forecast by Region (2022-2027)
      • 13.1.1 Global Cancer Tubulin Inhibitors Sales Volume Forecast by Region (2022-2027)
      • 13.1.2 Global Cancer Tubulin Inhibitors Sales Value Forecast by Region (2022-2027)
    • 13.2 North America Market Forecast
    • 13.3 Europe Market Forecast
    • 13.4 Asia Pacific Market Forecast
    • 13.5 Central & South America Market Forecast
    • 13.6 Middle East & Africa Market Forecast

    14 Key Participants Company Information

    • 14.1 Tocris Bioscience
      • 14.1.1 Company Information
      • 14.1.2 Cancer Tubulin Inhibitors Product Introduction
      • 14.1.3 Tocris Bioscience Cancer Tubulin Inhibitors Sales Volume, Price, Sales Value and Gross Margin (2019-2021)
      • 14.1.4 SWOT Analysis
    • 14.2 Seattle Genetics
      • 14.2.1 Company Information
      • 14.2.2 Cancer Tubulin Inhibitors Product Introduction
      • 14.2.3 Seattle Genetics Cancer Tubulin Inhibitors Sales Volume, Price, Sales Value and Gross Margin (2019-2021)
      • 14.2.4 SWOT Analysis
    • 14.3 Sanofi-Aventis
      • 14.3.1 Company Information
      • 14.3.2 Cancer Tubulin Inhibitors Product Introduction
      • 14.3.3 Sanofi-Aventis Cancer Tubulin Inhibitors Sales Volume, Price, Sales Value and Gross Margin (2019-2021)
      • 14.3.4 SWOT Analysis
    • 14.4 Roche
      • 14.4.1 Company Information
      • 14.4.2 Cancer Tubulin Inhibitors Product Introduction
      • 14.4.3 Roche Cancer Tubulin Inhibitors Sales Volume, Price, Sales Value and Gross Margin (2019-2021)
      • 14.4.4 SWOT Analysis
    • 14.5 Pierre Fabre
      • 14.5.1 Company Information
      • 14.5.2 Cancer Tubulin Inhibitors Product Introduction
      • 14.5.3 Pierre Fabre Cancer Tubulin Inhibitors Sales Volume, Price, Sales Value and Gross Margin (2019-2021)
      • 14.5.4 SWOT Analysis
    • 14.6 Modra Pharmaceuticals
      • 14.6.1 Company Information
      • 14.6.2 Cancer Tubulin Inhibitors Product Introduction
      • 14.6.3 Modra Pharmaceuticals Cancer Tubulin Inhibitors Sales Volume, Price, Sales Value and Gross Margin (2019-2021)
      • 14.6.4 SWOT Analysis
    • 14.7 Immunogen
      • 14.7.1 Company Information
      • 14.7.2 Cancer Tubulin Inhibitors Product Introduction
      • 14.7.3 Immunogen Cancer Tubulin Inhibitors Sales Volume, Price, Sales Value and Gross Margin (2019-2021)
      • 14.7.4 SWOT Analysis
    • 14.8 Genentech
      • 14.8.1 Company Information
      • 14.8.2 Cancer Tubulin Inhibitors Product Introduction
      • 14.8.3 Genentech Cancer Tubulin Inhibitors Sales Volume, Price, Sales Value and Gross Margin (2019-2021)
      • 14.8.4 SWOT Analysis
    • 14.9 Endocyte
      • 14.9.1 Company Information
      • 14.9.2 Cancer Tubulin Inhibitors Product Introduction
      • 14.9.3 Endocyte Cancer Tubulin Inhibitors Sales Volume, Price, Sales Value and Gross Margin (2019-2021)
      • 14.9.4 SWOT Analysis
    • 14.10 Eagle Pharmaceuticals
      • 14.10.1 Company Information
      • 14.10.2 Cancer Tubulin Inhibitors Product Introduction
      • 14.10.3 Eagle Pharmaceuticals Cancer Tubulin Inhibitors Sales Volume, Price, Sales Value and Gross Margin (2019-2021)
      • 14.10.4 SWOT Analysis
    • 14.11 Celgene
    • 14.12 Amgen
    • 14.13 Agensys
    • 14.14 Abraxis Biosciences

    15 Conclusion

      16 Methodology

      Covid-19 has impacted the supply and demand status for many industries along the supply chain. In this report a comprehensive analysis of current global Cancer Tubulin Inhibitors market in terms of demand and supply environment is provided, as well as price trend currently and in the next few years. Global leading players are profiled with their revenue, market share, profit margin, major product portfolio and SWOT analysis. From industry perspective this report analyses supply chain, including process chart introduction, upstream key raw material and cost analysis, distributor and downstream buyer analysis. This report also includes global and regional market size and forecast, major product development trend and typical downstream segment scenario, under the context of market drivers and inhibitors analysis. According to this survey, the global Cancer Tubulin Inhibitors market is estimated to have reached $ xx million in 2020, and projected to grow at a CAGR of xx% to $ xx million in 2027.

      Segmented by Category
      Docetaxel
      Trastuzumab Emtansine
      Abraxane
      Brentuximab Vedotin
      Cabazitaxel

      Segmented by End User/Segment
      Non Small Cell Lung Cancer
      Prostate Cancer
      Breast Cancer
      Colorectal Cancer
      Ovarian Cancer

      Segmented by Country
      North America
      United States
      Canada
      Mexico
      Europe
      Germany
      France
      UK
      Italy
      Russia
      Spain
      Asia Pacific
      China
      Japan
      Korea
      Southeast Asia
      India
      Australasia
      Central & South America
      Brazil
      Argentina
      Colombia
      Middle East & Africa
      Iran
      Israel
      Turkey
      South Africa
      Saudi Arabia

      Key manufacturers included in this survey
      Tocris Bioscience
      Seattle Genetics
      Sanofi-Aventis
      Roche
      Pierre Fabre
      Modra Pharmaceuticals
      Immunogen
      Genentech
      Endocyte
      Eagle Pharmaceuticals
      Celgene
      Amgen
      Agensys
      Abraxis Biosciences

      Buy now